Market Place
Sourcing Support
Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001
09 Feb 2024 //
PR NEWSWIRE
Hemab Announces First Patient Dosed in Phase 2 Study Investigating HMB-001
11 Dec 2023 //
PR NEWSWIRE
Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects
24 Jun 2023 //
PR NEWSWIRE
Hemab Therapeutics to Present New Preclinical Data on HMB-001
15 Jun 2023 //
PR NEWSWIRE
Hemab uses $135M series B to target neglected blood disorders
21 Feb 2023 //
FIERCE BIOTECH
Rare blood disorders biotech Hemab raises $135M, begins trek into clinic
20 Feb 2023 //
ENDPTS
Hemab doses first patient in Phase I/II trial of antibody for Glanzmann
11 Jan 2023 //
CLINICALTRIALSARENA
Hemab presents positive preclinical data on HMB-001 at EAHAD 2022 congress
07 Feb 2022 //
PHARMABIZ
Hemab Tx`s HMB-001 with Potential for Treatment of Rare Bleeding Disorders
04 Feb 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.